Recordati agreed to acquire worldwide rights to Signifor and Signifor LAR for the treatment of Cushing’s disease and acromegaly in adult patients.
- The agreement also covers the acquisition of worldwide rights to osilodrostat, an investigational innovative drug for the treatment of endogenous Cushing’s syndrome
- Upon completion of the transaction a consideration of $390 million will be due to Novartis
©2019 Bloomberg L.P. All rights reserved. Used with permission
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.